STAT+: Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer

Ivonescimab, developed by Akeso Therapeutics and Summit Therapeutics, reduced the risk of death by 34% in patients with squamous non-small cell lung cancer compared to standard treatment in a China-based clinical trial. Results were presented at the American Society of Clinical Oncology meeting and published in The Lancet, with Summit’s co-CEO highlighting the drug’s potential business value.